INTRODUCTION: Ulcerative colitis (UC) is increasing in African-Americans (AA). The objectives of this study were to assess disease extent and severity in UC by race. METHODS: Disease extent and severity was assessed in UC outpatients evaluated at the University of Maryland and Baltimore VA from 1997 to 2005. RESULTS: About 197 patients were identified; 47 were AA (23%). Of AA, 23% had proctitis, 23% had left-sided colitis, and 53% had extensive colitis compared to 10%, 31%, and 59% of Caucasians, respectively (P = 0.056). African-Americans were less likely to ever receive steroids (45% versus 62%; P = 0.065), be treated with > or = 2 courses of steroids (54% versus 68%; P = 0.242) or be steroid dependant (33% versus 46%; P = 0.304). After adjustment, only female gender (OR 0.32, [0.16-0.66]) and age at diagnosis (OR 2.50, [1.28-4.90]) were associated with extensive colitis. Being seen at UMMS (OR 5.10, [2.60-10.10]) was associated with steroid use. CONCLUSION: Race was not associated with extent of colitis or disease severity in UC.
INTRODUCTION:Ulcerative colitis (UC) is increasing in African-Americans (AA). The objectives of this study were to assess disease extent and severity in UC by race. METHODS: Disease extent and severity was assessed in UC outpatients evaluated at the University of Maryland and Baltimore VA from 1997 to 2005. RESULTS: About 197 patients were identified; 47 were AA (23%). Of AA, 23% had proctitis, 23% had left-sided colitis, and 53% had extensive colitis compared to 10%, 31%, and 59% of Caucasians, respectively (P = 0.056). African-Americans were less likely to ever receive steroids (45% versus 62%; P = 0.065), be treated with > or = 2 courses of steroids (54% versus 68%; P = 0.242) or be steroid dependant (33% versus 46%; P = 0.304). After adjustment, only female gender (OR 0.32, [0.16-0.66]) and age at diagnosis (OR 2.50, [1.28-4.90]) were associated with extensive colitis. Being seen at UMMS (OR 5.10, [2.60-10.10]) was associated with steroid use. CONCLUSION: Race was not associated with extent of colitis or disease severity in UC.
Authors: Leyla J Ghazi; Alison D Lydecker; Seema A Patil; Ankur Rustgi; Raymond K Cross; Mark H Flasar Journal: Dig Dis Sci Date: 2014-04-10 Impact factor: 3.199
Authors: Edward L Barnes; Bharati Kochar; Millie D Long; Joel Pekow; Ashwin Ananthakrishnan; Adjoa Anyane-Yeboa; Christopher Martin; Joseph Galanko; Hans H Herfarth; Michael D Kappelman; Robert S Sandler Journal: Inflamm Bowel Dis Date: 2018-11-29 Impact factor: 5.325
Authors: Hai Yun Shi; Alexander N Levy; Hirsh D Trivedi; Francis K L Chan; Siew C Ng; Ashwin N Ananthakrishnan Journal: Clin Gastroenterol Hepatol Date: 2017-06-08 Impact factor: 11.382
Authors: Edward L Barnes; Christina M Bauer; Robert S Sandler; Michael D Kappelman; Millie D Long Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: Edward L Barnes; Bharati Kochar; Millie D Long; Christopher F Martin; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2017-12 Impact factor: 7.290